Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02224625 · ClinicalTrials.gov registry record · Phase 3
Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth
A Phase 3 study, sponsored by Medline Industries.
- Completed
- Registry status
- Phase 3
- Development phase
- 249
- Enrollment target
NCT02224625: Completed Phase 3 study, sponsored by Medline Industries.
NCT02224625 is a Phase 3 study that has completed, run by Medline Industries. The registered enrollment target is 249 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02224625, a Phase 3 study, has completed, sponsored by Medline Industries.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 249 participants
- Enrollment target
Study Summary
Evaluating the irritation properties of CHG cloth. Some Subjects will also have the product applied to see if they become sensitized to repeated applications.
Primary Outcome
Irritation: 21 days of patching (total). A reviewer will assign a score based on an 8 point categorical scale to the areas treated at each visit. Sensitization: 35 days (21 days of patching followed by 14 days rest and subsequent patch). A reviewer will assign a score based on an 8 point categorical scale to the areas treated at each visit. SLS was not tested. Grade 0 = No irritation Grade 1 = Minimal erythema Grade 2 = Definite erythema Grade 3 = Erythema and papules Grade 4 = Edema Grade 5 =
Interventions
- OTHER Saline
- DRUG Active Comparator
- DRUG 2% CHG Cloth solution
- DEVICE Vehicle Cloth
- OTHER SLS
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 249 participants |
| Start Date | 2014-08 |
| Est. Completion | 2015-06 |
| Phase | Phase 3 |
What the finished NCT02224625 record still lists
NCT02224625 is an interventional study that assigns participants to a tested intervention. The registered 249 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (68% lower).
The record links to 0 conditions, and to 5 interventions - of which Saline is the first listed.
NCT02224625 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02224625 about?
NCT02224625 is a clinical study titled "Irritation and Sensitization of Chlorhexidine Gluconate (CHG) Cloth". Evaluating the irritation properties of CHG cloth. Some Subjects will also have the product applied to see if they become sensitized to repeated applications.
What is the current status of trial NCT02224625?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 249 participants. The study started on 2014-08. Estimated completion is 2015-06.
What interventions are being tested in trial NCT02224625?
The interventions under investigation include: Saline (OTHER), Active Comparator (DRUG), 2% CHG Cloth solution (DRUG), Vehicle Cloth (DEVICE), SLS (OTHER).
Who is sponsoring clinical trial NCT02224625?
This trial is sponsored by Medline Industries, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02224625's enrollment target sits among peer trials
249 1266th of 2000 higher than 735 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04628767 · 249 participants · Phase 2
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer
- NCT05834907 · 249 participants · NA
Hands and Hearts Together
- NCT06067555 · 249 participants · Early Phase 1
Intradermal Influenza Vaccination
- NCT06588478 · 249 participants · Phase 2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia